ID   SBC-1
AC   CVCL_1676
AS   CVCL_D230
SY   SBC1; Lc817; LC817
DR   BTO; BTO:0005442
DR   CLO; CLO_0037041
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472514
DR   cancercelllines; CVCL_1676
DR   Cell_Model_Passport; SIDM00365
DR   ChEMBL-Cells; CHEMBL3308214
DR   ChEMBL-Targets; CHEMBL2366327
DR   Cosmic; 713885
DR   Cosmic; 1995623
DR   Cosmic-CLP; 713885
DR   DepMap; ACH-002196
DR   EGA; EGAS00001000978
DR   GDSC; 713885
DR   GEO; GSM986190
DR   GEO; GSM1670404
DR   IARC_TP53; 27235
DR   JCRB; JCRB0816
DR   JCRB; NIHS0676
DR   LINCS_LDP; LCL-1865
DR   PharmacoDB; SBC1_1347_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1676
DR   PubChem_Cell_line; CVCL_1676
DR   Wikidata; Q54902178
RX   CelloPub=CLPUB00132;
RX   DOI=10.2482/haigan.22.53;
RX   DOI=10.4044/joma1947.104.9-10_905;
RX   PubMed=2540905;
RX   PubMed=8286010;
RX   PubMed=9290701;
RX   PubMed=9413215;
RX   PubMed=12569360;
RX   PubMed=17270020;
RX   PubMed=18937546;
RX   PubMed=20164919;
RX   PubMed=22399608;
RX   PubMed=25120651;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Problematic cell line: Possibly misidentified/contaminated. Shown to be identical to SBC-2 (JCRB web site and STR profile).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 20.4 hours (PubMed=8286010); ~40 hours (Note=Lot 11012007) (JCRB=JCRB0816).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Gly48Ter (c.142G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu112Ter (c.334G>T); ClinVar=VCV001730509; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys120Ter (c.358A>T); ClinVar=VCV000012363; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.47%; East Asian, North=73.66%; East Asian, South=25.87%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0676; true.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9
ST   D5S818: 9,11
ST   D7S820: 11,12
ST   TH01: 8,9
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_W531 ! SBC-2 [Human SCLC]
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   CelloPub=CLPUB00132;
RA   Kishimoto N., Ohnoshi T., Hiraki S., Miyake K., Ozawa S., Tamura T.,
RA   Numata K., Kawahara N., Tamura R., Miyamoto H., Nishii K., Kimura I.;
RT   "Establishment and characterization of five cell lines from human
RT   small cell carcinoma of the lung.";
RL   Nihon Haigan Gakkai 24:644-644(1984).
//
RX   DOI=10.2482/haigan.22.53;
RA   Hiraki S., Miyai M., Seto T., Tamura T., Watanabe Y., Ozawa S.,
RA   Ikeda H., Nakata Y., Ohnoshi T., Kimura I.;
RT   "Establishment of human continuous cell lines from squamous cell,
RT   adeno- and small cell carcinoma of the lung and the results of
RT   heterotransplantation.";
RL   Nihon Haigan Gakkai 22:53-58(1982).
//
RX   DOI=10.4044/joma1947.104.9-10_905;
RA   Kishimoto N.;
RT   "Studies on cell biology and chemotherapy of lung cancer using tissue
RT   culture techniques. Part 2. Biological characteristics of five newly
RT   established small cell lung cancer cell lines.";
RL   Okayama Igakkai Zasshi 104:905-913(1992).
//
RX   PubMed=2540905;
RA   Takahashi T., Obata Y., Sekido Y., Hida T., Ueda R., Watanabe H.,
RA   Ariyoshi Y., Sugiura T., Takahashi T.;
RT   "Expression and amplification of myc gene family in small cell lung
RT   cancer and its relation to biological characteristics.";
RL   Cancer Res. 49:2683-2688(1989).
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9413215;
RA   Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K.,
RA   Hiraki A., Ueoka H., Harada M.;
RT   "Small cell lung cancer can express CD34 antigen.";
RL   Anticancer Res. 17:3627-3632(1997).
//
RX   PubMed=12569360; DOI=10.1038/sj.onc.1206106;
RA   Funakoshi T., Tachibana I., Hoshida Y., Kimura H., Takeda Y.,
RA   Kijima T., Nishino K., Goto H., Yoneda T., Kumagai T., Osaki T.,
RA   Hayashi S., Aozasa K., Kawase I.;
RT   "Expression of tetraspanins in human lung cancer cells: frequent
RT   downregulation of CD9 and its contribution to cell motility in small
RT   cell lung cancer.";
RL   Oncogene 22:674-687(2003).
//
RX   PubMed=17270020; DOI=10.1111/j.1349-7006.2006.00383.x;
RA   Koshida S., Kobayashi D., Moriai R., Tsuji N., Watanabe N.;
RT   "Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast
RT   and lung cancer tissues detected using quantitative analysis.";
RL   Cancer Sci. 98:315-320(2007).
//
RX   PubMed=18937546; DOI=10.1089/jir.2008.0035;
RA   Kubo T., Ichimiya S., Tonooka A., Nagashima T., Kikuchi T., Sato N.;
RT   "p63 induces CD4+ T-cell chemoattractant TARC/CCL17 in human
RT   epithelial cells.";
RL   J. Interferon Cytokine Res. 28:725-732(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22399608;
RA   Tsuchida T., Yamane H., Ochi N., Tabayashi T., Hiraki A., Nogami N.,
RA   Takigawa N., Kiura K., Tanimoto M.;
RT   "Cytotoxicity of activated natural killer cells and expression of
RT   adhesion molecules in small-cell lung cancer.";
RL   Anticancer Res. 32:887-892(2012).
//
RX   PubMed=25120651; DOI=10.3892/ol.2014.2234;
RA   Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K.,
RA   Shibata H., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation and silencing of IRF8 expression in non-small
RT   cell lung cancer.";
RL   Oncol. Lett. 8:1025-1030(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//